⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106444 | 0.79 | — | — | |
| SCHEMBL7438406 | 0.78 | — | — | |
| SCHEMBL16944043 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL635332 | 0.73 | — | — | |
| SCHEMBL2745822 | 0.71 | — | — | |
| SCHEMBL1048076 | 0.71 | — | — | |
| SCHEMBL12741116 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL15793305 | 0.71 | — | — | |
| SCHEMBL21488420 | 0.71 | — | — | |
| SCHEMBL10903390 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | claimed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| CN-1289336-A | Chemokine receptor antagonists and methods of use therefor | LEUKOSITE INC (US) | 2001-03-28 | — | — | CN | disclosed |